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Background: We used four years of paediatric severe acute respiratory illness (SARI) 73 
sentinel surveillance in Blantyre, Malawi to identify factors associated with clinical severity 74 
and co-viral clustering. 75 
Methods: From January 2011 to December 2014, 2363 children aged 3 months to 14 years 76 
presenting to hospital with SARI were enrolled. Nasopharyngeal aspirates were tested for 77 
influenza and other respiratory viruses. We assessed risk factors for clinical severity and 78 
conducted clustering analysis to identify viral clusters in children with co-viral detection.  79 
Results: Hospital-attended influenza-positive SARI incidence was 2.0 cases per 10,000 80 
children annually; it was highest children aged under 1 year (6.3 cases per 10,000), and HIV-81 
infected children aged 5 to 9 years (6.0 cases per 10,000). 605 (26.8%) SARI cases had 82 
warning signs, which were positively associated with HIV infection (adjusted risk ratio 83 
[aRR]: 2.4, 95% CI: 1.4, 3.9), RSV infection (aRR: 1.9, 95% CI: 1.3, 3.0) and rainy season 84 
(aRR: 2.4, 95% CI: 1.6, 3.8). We identified six co-viral clusters; one cluster was associated 85 
with SARI with warning signs.  86 
Conclusions: Influenza vaccination may benefit young children and HIV infected children in 87 
this setting. Viral clustering may be associated with SARI severity; its assessment should be 88 
included in routine SARI surveillance.  89 
 90 
 91 
 92 
  93 
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Background 94 
It is estimated that worldwide, the case-fatality of severe pneumonia in children <5 years is 95 
8·9%, which in 2011 amounted to 1.26 million deaths[1]. Much of this burden falls on sub-96 
Saharan Africa where severe acute respiratory infection (SARI), including pneumonia, is a 97 
leading cause of childhood hospital attendance and death [2]. Although laboratory diagnostic 98 
facilities are rarely available in such settings, sentinel surveillance using multiplex molecular 99 
diagnostics has recently provided considerable insight into the true burden of disease and the 100 
complexity of SARI aetiology. Respiratory syncytial virus (RSV), parainfluenza viruses, 101 
rhinoviruses, influenza viruses and adenovirus have been commonly detected in SARI 102 
surveillance across the African continent [3-8]. While there are a few viruses where detection 103 
in respiratory disease cases is likely causal (e.g., influenza, RSV)[9, 10], for other commonly 104 
identified viruses causality has been difficult to determine. Use of multiplex assays has led to 105 
an increasing realisation that children with SARI commonly carry multiple viral pathogens 106 
which may potentially contribute to disease. 107 
 108 
In the context of a low-income population with multiple drivers of immune compromise (e.g., 109 
HIV, malnutrition, malaria) [11], we conducted active surveillance at a large urban teaching 110 
hospital in Malawi to estimate the incidence of childhood SARI and explore the association 111 
of SARI clinical severity with HIV and clustering of respiratory viral co-infection. While 112 
previous studies have focused on children aged <5 years, we included children aged 3 months 113 
to 14 years in our analysis, to better capture the total burden and identify age groups 114 
particularly at-risk. 115 
 116 
Methods 117 
Study site, population and study design 118 
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QECH is the only government inpatient facility for Blantyre (population ~500,000 children 119 
aged <15 years); it offers care free at the point of delivery. Overall, 13% of children aged <5 120 
years in Malawi are moderately to severely underweight and 4% are wasted; 80.9% of 121 
children aged 12-23 months have received all Expanded Program on Immunization 122 
vaccinations [12]. There is no national routine influenza vaccination in Malawi. In 2010, an 123 
influenza A(H1N1)pdm09 monovalent vaccine campaign achieved 74% coverage in pregnant 124 
women, and 7% of the overall population [13]. An estimated 2.5% of children aged <15 years 125 
are HIV infected [14]; HIV prevalence in children < 5 years on QECH non-surgical 126 
paediatric wards is estimated at 6%. Blantyre has two distinct weather seasons, a rainy season 127 
(January to April) and a cool dry season (May to August). Overall 25.2% of Paediatric 128 
Accident and Emergency Unit (PAEU) patients have a positive malaria blood slide; malaria 129 
presentations to the PAEU peak from December to May.   130 
 131 
Patients aged 3 months to 14 years presenting during surveillance hours (weekdays, 8 am – 1 132 
pm) from January 2011 through December 2014 were screened. Consecutive patients 133 
fulfilling the SARI case definition were recruited (maximum 5 per day). Demographic and 134 
clinical data were captured through an electronic data collection system [15]. Nasopharyngeal 135 
aspirates (NPA) were obtained and tested for influenza viruses; from 2011 to 2013 NPAs 136 
were also tested by multiplex assay for respiratory pathogens. Thick blood films for malaria 137 
were performed on all children.  138 
 139 
SARI was defined as (a) an acute illness with symptom onset <7 days and (b) reported or 140 
recorded fever ≥ 38o C (or hypothermia in children < 6 months). Additional criteria for SARI 141 
varied by age. In children < 6 months, additional criteria were: (c) cough or apnea - or - (d) 142 
any respiratory symptom requiring hospitalization.  In children 6 to 59 months, an additional 143 
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criterion was: (c) clinician diagnosed lower respiratory infection. In children 6 to 14 years, 144 
additional criteria were: (c) cough  - or -  sore throat and (d) shortness of breath  - or  - 145 
difficulty breathing. SARI with warning signs was considered clinically more severe and 146 
defined as admission to hospital - or -  chest recession - or - blood oxygen saturation of  147 
<90%.  In this resource-limited setting, some patients with severe illness requiring admission 148 
were sent home. Thus, hospital-attendance (not admission) was required for study enrolment. 149 
 150 
Laboratory procedures 151 
NPAs were stored at -80C in Universal Transport Medium (Copan, Brescia, Italy)[16] and 152 
batch-tested for influenza viruses by real-time reverse transcription polymerase chain 153 
reaction (rRT-PCR). Total nucleic acids were extracted from 300μl aliquots of each specimen 154 
with the Qiagen BioRobot Universal System using the QIAamp One-For-All nucleic acid 155 
kit (Qiagen ltd., Manchester, UK). The quantity of nucleic acid used per reaction was 5 μl for 156 
the CDC Human Influenza rRT-PCR diagnostic panel (CDC Influenza Division) detecting 157 
influenza A and B viruses and influenza A subtypes H1, H3, 2009H1 and H5N1 and 10 μl for 158 
the FTD respiratory pathogens 33 kit (Fast-track Diagnostics Ltd., Luxembourg). Details on 159 
sample processing with by FTD rRT-PCR are provided in Appendix 1. HIV serostatus was 160 
assessed by rapid test  (Alere DetermineTM HIV-1/2 and Trinity Biotech Uni-GoldTM HIV) 161 
according to WHO guidelines[17]. PCR for detection of HIV RNA was performed in 162 
children aged 3-11 months with a positive HIV rapid test. HIV infection was defined as a 163 
positive HIV rapid test (in the absence of a negative HIV PCR); data was not collected on 164 
HIV exposure. 165 
 166 
Ethics Approval 167 
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Ethics approval for this study was obtained from the Liverpool School of Tropical Medicine 168 
Research Ethics Committee (Approval #RETH000790), the University of Malawi College of 169 
Medicine Research Ethics Committee (COMREC, Approval #958) and CDC through a 170 
reliance on COMREC. Informed consent was obtained from guardians of all study 171 
participants. 172 
 173 
Data analysis 174 
Numerators for minimum SARI incidence estimates were generated by summing the number 175 
of cases resident in Blantyre within strata of age category and HIV status. Numerators were 176 
adjusted by multiplying by the reciprocal of the daily proportion of recruited cases among all 177 
SARI cases attending the PAEU. Denominators for HIV and age strata were derived by 178 
applying age-specific HIV prevalence estimates to census figures for Blantyre District’s 179 
population aged 0-14 years [18]. The former were obtained by apportioning total HIV 180 
prevalence among Malawian children aged <15 years [14] according to the age-distribution 181 
of paediatric HIV from Mozambique which borders Malawi, and has a similarly severe HIV 182 
epidemic [19] [20]. Estimates of age-specific HIV prevalence were unavailable for Malawi 183 
for the study period. Incidence was obtained by dividing numerators by denominators and 184 
multiplying by 10,000; HIV-associated Incidence Rate Ratios (IRRHIV) were calculated by 185 
dividing incidence in HIV infected strata by incidence in HIV un-infected strata; 95% 186 
confidence intervals (95% CIs) of incidence and IRRHIV were generated with 1000 bootstrap 187 
samples. 188 
 189 
Data analysis was performed using SAS® 9.3 (SAS Institute, Cary NC). Temporal trends in 190 
weekly sample counts for SARI cases were assessed by plotting 5-week moving averages of 191 
sample counts by recruitment week. We developed two logistic regression models with a 192 
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binary outcome factor for the child’s clinical status. The first outcome represented SARI with 193 
warning signs (i.e. clinical markers of very severe illness) vs. SARI without warning signs. 194 
The second outcome represented influenza positive SARI vs. influenza negative SARI. Auto-195 
regressive correlation of residuals was removed by introducing a patient-level Kernel 196 
weighted moving average of the prior probability of case status. Parsimonious models were 197 
developed by stepwise logistic regression, retaining age, sex a priori, and explanatory factors 198 
with a 2-sided p-value of <0.05. Adjusted relative risk ratios for factors associated with the 199 
outcomes, were derived from these models.  200 
 201 
Detection of multiple viruses in SARI is common, with many possible combinations of viral 202 
carriage. Conventional statistical techniques (eg. regression models, covariance matrices and 203 
temporal plots) have limited capacity to quantify, characterize or identify factors associated 204 
with viral carriage groupings. To assess multiple virus carriage clusters in our setting, we 205 
performed ‘nearest-neighbour’ discrete hierarchical cluster analysis in patients with viral co-206 
detection using Gower’s distance [21]. Distance was based on similarity of viral pathogens 207 
detected in the nasopharynx of SARI patients; each patient was a member of only one cluster. 208 
We defined clusters as those which increased the R-squared by >0.05 (using Ward’s method); 209 
to improve precision, 10% of observations with the lowest densities were discarded. Using, 210 
univariate logistic regression we identified factors associated with cluster membership.  211 
 212 
Results 213 
SARI population 214 
From 1 January 2011 to 31 December 2014, 2363 SARI cases (median age: 15 months, 215 
interquartile range [IQR]: 8 - 27 months) were recruited. In total, 605/2260 (26.8%) SARI 216 
cases had clinical warning signs (Table 1, Consort diagram –Appendix 2). Warning signs 217 
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were determined as follows: 489/605 (80.8%) were hospitalised (median duration of stay 2 218 
days [IQR: 1, 3]); 37/605 (6.1%) had blood oxygen saturation <90%; 75/605 (12.4%) had 219 
chest recession; 4/605 (<1%) had both of these clinical features. In cases aged 3 to <12 220 
months, 17/247 (6.9%) had a positive HIV test result compared to 29/563 (5.2%) cases aged 221 
12 to <36 months, 45/1050 (4.3%) cases aged 36 to 59 months, 19/241 (7.9%) cases aged 5 222 
to 9 years and 18/103 (17.5%) cases aged 10 to 14 years.  Eight of 17 HIV infections in cases 223 
aged 3 to <12 months (47.1%) were confirmed by PCR.  224 
  225 
Viruses detected in association with SARI 226 
We detected influenza viruses in 266/2363 (11.3%) SARI cases. When tested for the 227 
extended panel of pathogens, influenza viruses A and B (any type) were detected in 201/1835 228 
(10.9%), rhinoviruses in 358/1835 (19.5%), RSV in 220/1835 (11.9%) and adenovirus in 229 
162/1835 (8.8%). In 542/1835 (30%) SARI cases, no viral pathogen was detected (Table 2).   230 
 231 
Seasonality of influenza and RSV 232 
Plots of weekly influenza positive SARI cases suggest both unimodal and bimodal (2 peaks 233 
per year) seasonality. Weekly influenza-positive SARI cases increased during the rainy 234 
season (January to April) in all four years of surveillance. A second peak of influenza-235 
positive SARI cases occurring in September to October was confined to 2013 and 2014 236 
(Figure 1). In multivariable analysis, influenza detection in SARI increased in the rainy 237 
season (adjusted risk ratio [aRR]: 3.3, 95% CI: 1.9, 5.4) and the cool dry months (May to 238 
August) (aRR: 2.1, 95% CI: 1.2, 3.6), compared to September to December (Table 3). 239 
Influenza detection in SARI was significantly higher in the rainy season compared to the cool 240 
dry season (aRR: 1.6, 95% CI: 1.0, 2.5). The predominance of influenza virus types varied 241 
within and between years. Influenza A(H1N1)pdm09 was most prevalent in the first half of 242 
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2011 and 2013; influenza A(H3N2) and influenza B viruses were most prevalent in 2012, the 243 
latter half of 2013 and in 2014.  In contrast, RSV infection displayed regular seasonality, with 244 
peaks in the first half of the rainy season (January to March) (Figure 1). 245 
 246 
Incidence estimates for SARI and respiratory virus-associated SARI 247 
SARI incidence was 17.5 cases per 10,000 children annually, with highest incidence in 248 
children aged 3 to 11 months (89.5, 95% CI: 85.8, 93.0). Influenza-positive SARI incidence 249 
was 2.0 cases per 10,000 children annually and was highest in children aged 3 to 11 months 250 
(6.3, 95% CI: 5.3, 7.6). Incidence of RSV positive SARI per 10,000 children annually was 251 
4.6 (95% CI: 0.1, 15.8) and was highest in children 3 to 11 months (17.3, 95% CI: 13.7, 18.6) 252 
(Table 4).  253 
 254 
Risk factors for SARI with warning signs and virus-associated SARI 255 
We found 390/1505 (25.9%) SARI cases had warning signs, among whom 309/390 (79.2%) 256 
were hospitalised. In multivariable analysis, RSV was the only pathogen associated with 257 
SARI with warning signs (aRR: 1.9, 95% CI: 1.3, 3.0). Nevertheless, 52/249 (20.9%) 258 
influenza positive SARI cases required hospitalisation. A positive HIV test was associated 259 
with a 2-fold increased risk of SARI with warning signs (aRR: 2.4, 95% CI: 1.4, 3.9) (Table 260 
5) as well as increased incidence of SARI, SARI with warning signs and influenza positive 261 
SARI (Table 4). HIV-associated incidence rate ratios (IRRhiv) rose with increasing age. The 262 
IRRshiv for SARI with warning signs was 2.6 in children 3-11 months compared to 37.7 in 263 
children 10-14 years. In children aged >5 years, incidence of hospital-attended influenza 264 
positive SARI was at least 8-fold higher in HIV infected children compared to the HIV 265 
uninfected. There was no difference in the incidence of RSV-positive SARI between HIV 266 
infected and HIV uninfected children.  267 
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 268 
In multivariable analysis, controlling for aetiology, SARI patients recruited during the rainy 269 
season (January-April) were more than twice as likely to have warning signs compared to 270 
patients enrolled during September-December (aRR: 2.4, 95% CI: 1.6, 3.8) (Table 5). Peaks 271 
in RSV and influenza activity corresponded to peaks in the occurrence of SARI with warning 272 
signs (Figure 1). Detection of RSV in cases of SARI warning signs was much higher during 273 
the rainy season (39.8%) compared to other times of year (5.9%). 274 
 275 
The adjusted risk ratio for positive influenza test in SARI increased with older age and rainy 276 
season of recruitment (Table 3). After adjusting for age, gender and HIV status, rainy season 277 
recruitment was significantly associated with SARI with warning signs in influenza positive 278 
SARI patients (aRR:3.42, 95% CI: 1.37, 8,53 – analysis not shown). In adjusted analysis, 279 
influenza A (H1N1)pdm09 virus was associated with double the risk of SARI with warning 280 
signs, compared to other influenza sub-types (aRR:2.10, 95% CI: 0.98, 4.53 – analysis not 281 
shown). 282 
 283 
Co-viral infection, viral clustering and clinical severity in SARI 284 
Detection of two or more viral pathogens by multiplex PCR occurred in 362/1835 (19.7%) 285 
SARI cases.  Viral co-detection was highest in SARI cases positive for coronaviruses 286 
229(70.6%) and enteroviruses (79.7%). Viral co-detection was least common in SARI cases 287 
testing positive for influenza A(H1N1)pdm09 virus (27.3%), influenza A (H3N2) virus 288 
(29.0%) and RSV (29.5%) (Table 2).    289 
 290 
Viral co-detection per se was not associated with warning signs in SARI (Table 5). We used 291 
discrete hierarchical cluster analysis based on similarity of viral pathogens detected by 292 
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multiplex PCR assay in SARI cases to explore whether particular groupings of viruses were 293 
associated with warning signs, host or seasonal factors. We identified six clusters, which 294 
accounted for 48.3% of the total variation in viral pathogen test results in children with co-295 
viral detection. Cluster size ranged from 23 to 96 members; smaller clusters had fewer viral 296 
pathogens and lower within-cluster heterogeneity. Clusters were distinguishable by the type 297 
of viral pathogens detected. For example, 80% of influenza A (H3N2) virus was found in 298 
Cluster A; >65% of bocavirus detected was found in Cluster E (Appendix 3).  299 
 300 
Cluster membership was significantly associated with clinical and temporal factors (Figure 301 
2). Among children with co-viral detection, membership in Cluster D (characterized by 302 
influenza A(H1N1)pdm09 virus, RSV, coronaviruses 43 and 63) was associated with nearly 303 
double the risk of SARI with warning signs (OR: 1.9, 95% CI: 1.2, 3.5- analysis not shown), 304 
compared to other clusters. In Cluster D, 47/70 (67%) of members had RSV or influenza 305 
A(H1N1)pdm09 virus infection (Appendix 3); 11.4% of members had RSV/ influenza 306 
A(H1N1)pdm09 virus co-infection, accounting for all such co-infections in SARI. Rainy 307 
season recruitment was significantly associated with Cluster D, while dry season recruitment 308 
was significantly associated with Cluster B (characterized by parainfluenza viruses 2 and 3). 309 
Clusters were also significantly associated with temporal peaks in viral pathogen activity. For 310 
example, 65% of Cluster A members were recruited during a peak in influenza A(H3N2) 311 
virus activity occurring from September to December in 2013 (Figures 1 and 2), compared to 312 
13.3% of other children with co-viral detection. Cluster membership was not associated with 313 
host factors (age, gender, HIV status, underweight). 314 
 315 
Discussion  316 
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Hospital-attended SARI was common in this urban sub-Saharan African setting, particularly 317 
in infants 3-11 months, in whom incidence was 91.7 cases per 10,000 children annually. 318 
Similar to studies from other settings, influenza viruses and RSV were important SARI-319 
associated pathogens [5-8, 22, 23], with prevalence rates of 11% and 12%, respectively. As 320 
elsewhere, HIV infection increased risk of SARI and presence of warning signs in SARI 321 
cases [24-26].  Among older children, HIV greatly increased risk of influenza positive SARI, 322 
consistent with data from South Africa[25].   323 
 324 
Viral co-infection occurred in almost 20% of SARI cases, highlighting its potential impact in 325 
the development or clinical worsening of SARI [27]. Although co-viral detection per se, was 326 
not associated with clinical severity or season, we found one viral cluster, characterized by a 327 
high proportion of RSV and influenza A(H1N1)pdm09 virus infection, which was 328 
significantly associated with clinical warning signs and rainy season recruitment. Cluster 329 
members co-infected with RSV and influenza A(H1N1)pdm09 virus had a higher rate of 330 
warning signs, but the number of co-infected individuals (within the cluster and the entire 331 
sample) was too small to formally test for interaction. It is unclear therefore whether clinical 332 
severity in this cluster resulted from biological interaction of pathogens, additive risks from 333 
each pathogen or other underlying factors. Clusters clearly mapped to peaks and troughs in 334 
individual pathogen activity. We suggest that this viral clustering, which was associated 335 
temporal dynamics of pathogen activity may have arisen from complex virus-virus and host-336 
virus pathogen interactions.  337 
 338 
Clinical severity in SARI demonstrated seasonal peaks, coinciding with rainy season peaks in 339 
RSV activity. RSV was detected in 40% of SARI cases with warning signs recruited during 340 
the rainy season compared to 6% recruited other times of year. Thus RSV may drive rainy 341 
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season increases in clinical severity in paediatric SARI in our setting, consistent with studies 342 
elsewhere in sub-Saharan Africa [28, 29]. Nevertheless, rainy season remained independently 343 
associated with increased risk of warning signs in SARI in multivariable analysis controlling 344 
for RSV, HIV and other viral pathogens. Therefore, the observed rainy season excess of 345 
clinical severity in SARI is in part attributable to unmeasured factors. We speculate that these 346 
factors include other intervening illnesses and seasonal malnutrition (in Malawi the rainy 347 
season coincides with the post-harvest ‘lean season’[30]). However, we cannot exclude 348 
seasonal differences in healthcare utilisation. 349 
 350 
We acknowledge that our study has limitations. We did not recruit children aged < 3 months, 351 
in whom SARI-related deaths are known to be elevated[31]. We were unable to determine the 352 
role of bacterial pathogens in SARI, as we lacked laboratory data and systematic radiological 353 
data to identify probable infection in the context of a very high prevalence of bacterial 354 
carriage. Our estimates of SARI incidence by HIV strata were based on Mozambican 355 
paediatric HIV prevalence rates as we lacked data from Malawi. Nevertheless, Malawi and 356 
Mozambique have similar rates of antenatal HIV prevalence[12, 32, 33], and have similarly 357 
high rates of HIV-infected pregnant women accessing antiretroviral treatment[34]. We did 358 
not assess the impact of HIV exposure on SARI risk in HIV uninfected children. HIV 359 
exposure was associated with higher SARI incidence and greater SARI severity in HIV 360 
uninfected South African children[35].  361 
  362 
In conclusion, SARI is common in this high HIV prevalence setting, where influenza viruses, 363 
rhinoviruses and RSV were the most prevalent viruses detected. HIV greatly increased risk of 364 
influenza-associated SARI in children, therefore yearly influenza vaccination should be 365 
considered in routine paediatric HIV clinical care. Influenza vaccination in HIV infected 366 
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children is safe, however has low efficacy (< 20%) and may only be immunogenic in older 367 
children and adolescents with virological suppression [36-38]. Viral co-infection was 368 
common with one co-viral cluster associated with  clinical severity in SARI cases. In this 369 
context, there is considerable potential for the use of multiplex respiratory virus assays in 370 
tandem with cluster analysis to reveal multiple-pathogen associated outbreaks and disease 371 
burden. This approach may expose the potential for synergistic effects of vaccine strategies 372 
that disrupt viral clusters. Vaccine probe studies to assess the impact of viral co-infection on 373 
clinical severity, could clarify complex pathogen and host interrelationships and reveal the 374 
true burden of disease. 375 
 376 
Disclaimer:  The findings and conclusions in this report are those of the authors and do not 377 
necessarily represent the official position of the Centers for Disease Control and Prevention. 378 
 379 
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Instructions for figures:  
 
The three files 'PanelA_Influenza(All Types).png', 'Panel B_Influenza Type by week.png' 
and ' PanelC_RSV.png' form Figure 1. The title of figure 1 is 'Seasonal plots of SARI with 
warning signs, influenza and RSV in paediatric SARI cases, Blantyre, Malawi, 2011-
2014'. 
 
For 'PanelA_Influenza(All Types).png' the panel title is 'A. Influenza (All Types)'; for the 
legend please note that the red line is 'Influenza positive SARI', the dotted black line is 
SARI with warning signs and the dotted grey line is SARI cases tested. 
 
For 'Panel B_Influenza Type by week.png' the panel title is 'B. Influenza Type by Week'; 
for the legend please note that that red bars are for 'A (H1N1)pdm09', green bars are 
for 'A (H2N3)', yellow bars are for 'B' and purple bars are for 'Other types'. 
 
For 'PanelC_RSV.png' the panel title is 'C. RSV';  for the legend please note that the red 
line is 'RSV positive SARI', the dotted black line is SARI with warning signs and the 
dotted grey line is SARI cases tested. 
 
The file ‘Figure 2 Dendrogram of co-viral clusters.png’ is for figure 2. The title of the 
figure is ‘Figure 2. Dendrogram of co-viral clusters’. The notes with the title are: ‘Six co-
viral clusters (A-F) were identified in 362 paediatric SARI cases, in whom >2 viral 
pathogens were detected in the nasopharynx. Each SARI case is a member of only 
cluster; clusters membership is based on similarity of viral pathogens detected. As 
shown here, characteristics such as SARI severity, number of viruses detected per child, 
and particular season and year of recruitment are more common in some clusters than 
others.’  
 
For Figure 2’s legend, referring to the first line of coloured bars, green bars are ‘SARI 
without warning signs’ and red bars are ‘SARI with warning signs’; referring to the 
second line of coloured bars, bluish-grey bars are ‘Number of viruses detected <3’ and 
orange bars are ‘Number of viruses detected >3’; referring to the third line of coloured 
bars,   lavendar bars are ‘Recruited in rainy season’ and yellow bars are ‘Not recruited in 
rainy season’; referring to the fourth line of coloured bars, grey bars are ‘recruited in 
2011’, blue bars are ‘recruited in 2012’, pink bars are ‘recruited in 2013’ and light green 
bars are ‘recruited in 2014’.  
 
For the file named ‘Appendix 2 CONSORT Diagram.png’ the title is, ‘Appendix 2. 
CONSORT Diagram of data analyses’.  
 
For the file named, ‘Appendix 3.png’ the title is, ‘Appendix 3. Viral pathogens detected in 
six clusters identified by discrete hierarchical cluster analysis of paediatric SARI cases 
with co-viral detection’.  For the legend,  BocaV is ‘Bocavirus’, HMPV is ‘Human 
metapneumo virus’, Cor63 is ‘Coronavirus 63’, H1N1 is ‘Influenza A(H1N1)pdm09’,  AV  
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is ‘Adenovirus’, Para 3 is ‘Parainfluenza virus 1’, Cor43 is ‘Coronavirus 43’, RSV is 
‘Respiratory syncytial virus’, PV is ‘Parechovirus’, Para 2 is ‘Parainfluenza virus 2’, FluC 
is ‘Influenza C’, Rhino is ‘Rhinovirus’, Cor229 is ‘Coronavirus 229’ and H3 is ‘Influenza A 
(H2N3)’. 
 
 
 
 
Table 1. Paediatric severe acute respiratory illness (SARI) patient characteristics by clinical severity and hospitalisation 
status, Blantyre, Malawi, 2011-2014 
 
All 
N(%)3 
 
SARI without 
warning signs1 
N(%) 
SARI with 
warning signs 
N(%) 
 
 
p-value2 
 Non-
Hospitalised 
SARI  
N(%) 
Hospitalised 
SARI  
N(%) p-value2 
Total 2260  1655 605   1771 489  
Female 1134 (43.0)  850 (51.4) 205 (33.9) 0.011  855 (48.3) 205 (41.9) 0.017 
  
        
Age 
 
        
 3 to <6 months 265 (11.7)  207 (12.6) 58 (9.6)   240 (12.8) 43 (8.8)  
 6 to <12 months 584 (25.8)  423 (25.6) 161 (26.6)   483 (25.8) 129 (26.4)  
 12 to <36 months 1077 (47.7)  777 (46.9) 300 (49.6)   862 (46.0) 244 (49.9)  
 36 to <60 months 248 (10.9)  192 (11.6) 56 (9.3)   212 (11.3) 44 (9.0)  
 5 to 14 years 86 (3.8)  56 (3.4) 30 (4.9) 0.057  77 (4.1) 29  (5.9) 0.023 
  
        
Season of recruitment 
 
        
 Sep-Dec 739 (32.7)  554 (33.4) 185 (30.6)   648 (34.6) 136 (27.8)  
 Jan to Apr (rain) 783 (34.6)  521 (31.4) 262 (43.3)   587 (31.3) 222 (45.4)  
 May-Aug 738 (32.7)  580 (35.0) 158 (26.1) <0.001  639 (34.1) 131 (26.8) <0.001 
  
        
HIV Positive4 120 (5.6)  65 (4.2) 55 (9.8) <0.001  80 (4.6) 48 (10.6) <0.001 
  
        
Weight for age <2 SD4 449 (20.9)  325 (20.2) 124 (22.9) 0.169  353 (20.5) 98 (22.4) 0.370 
  
        
Malaria positive4 78 (3.5)  47 (2.9) 31 (5.3) 0.007  52 (2.9) 27 (5.6) 0.006 
  
        
RSV PCR positive4 220 (11.9)  130 (9.4) 90 (19.9) <0.001  146 (9.9) 74 (20.9) <0.001 
          
Influenza PCR positive 258 (11.4)  199 (12.0) 59 (9.8) 0.133  217 (11.6) 50 (10.2) 0.399 
  Year3,5 
 
        
   2011 25 (8.8)  10 (7.3) 15 (9.3) 0.531  11 (6.1) 14 (11.8) 0.079 
   2012 30 (6.2)  28 (6.7) 3 (2.8) 0.121  29 (6.5) 2 (2.5) 0.167 
   2013 141 (16.2)  111 (15.6) 30 (19.5) 0.229  117 (15.8) 24 (18.6) 0.431 
   2014 70 (10.5)  59 (12.0) 11 (6.0) 0.024  60 (11.8) 10 (6.1) 0.040 
Type/Subtype 
 
        
 Influenza A 
 
        
   H1N1pdm09 44 (2.0)  25 (1.5) 19 (3.1)   28 (1.5) 18 (3.7)  
   H3N2 106 (4.7)  90 (5.4) 16 (2.6)   101 (5.4) 11 (2.3)  
   A (Unsubtyped) 4 (0.2)  3 (0.2) 1 (<0.1)   3 (0.2) 1 (0.2)  
Influenza B 101 (4.3)  81 (4.9) 20 (3.3)   85 (4.5) 17 (3.5)  
Influenza A & B  3 (0.1)  0 (0) 1 (<0.1)   0 (0) 3 (0.6)  
  
        
Clinical features4 
 
        
 Recorded fever 1048 (46.4)  618 (37.3) 430 (71.1) <0.001  708 (39.9) 340 (69.5) <0.001 
 Fast breathing 1805 (79.8)  1318 (79.6) 487 (80.5) 0.652  1398 (78.9) 407 (83.2) 0.036 
 Nasal flaring 569 (25.2)  167 (10.1) 402 (66.5) <0.001  230 (12.9) 339 (69.3) <0.001 
 Vomiting/ diarrhoea 392 (17.4)  264 (15.9) 128 (21.2) 0.004  287 (16.2) 105 (21.5) 0.007 
1. SARI with warning signs determined in 2260 patients with documented clinical severity and hospitalisation status 
2. P-values of difference between SARI with warning signs and SARI without warning signs, and between hospitalised and non-hospitalised SARI 
3. Percentages represent factor column totals, or the per cent of  all SARI cases assessed for the factor; for influenza by year percentages represent per     
    cent of column total within year 
4. HIV was measured in 2143 patients; weight-for-age Z score  was  measured in 2122 patients  aged 3 to 59 months;  malaria was measured in 2239 patients;  
    RSV was measured in 1835 patients recruited from 2011-2013;   
5. Fisher’s exact test used to compare yearly influenza prevalence by clinical severity and hospitalisation status 
 Table 2. Matrix of mono and co-detection of viral pathogens by multiplex PCR in 1835 paediatric severe acute respiratory illness (SARI) cases in Blantyre, Malawi, 2011-20141 
 
Influenza A 
(H3N2) 
Influenza 
B 
Influenza 
A 
(H1N1) 
pdm09 
Influenza 
C 
Boca-
virus 
Corona-
virus 
229 
Corona-
virus 43 
Coronav
irus 63 
Entero-
viruses 
Adeno-
virus 
Human 
meta-
pnuemo 
virus 
Para-
influenza 
virus 1 
Para-
influenza 
virus 2 
Para-
influenza 
virus 3 
Para-
influenza 
virus 4 
 
 
Parecho
-viruses RSV 
Rhino-
virus 
Influenza A (H3N2) 66                  
Influenza B  0 38                 
Influenza A (H1N1)pdm09  1  1 32                
Adenovirus  0  0  0 9               
Bocavirus  4  4  0  0 49              
Coronavirus 229  0  1  0  0  1 5             
Coronavirus 43  7  0  1  0 15 3 38            
Coronavirus 63  2  2  0  0  3 2 5 16           
Enteroviruses  1  3  1  1  5 1 5  3 13          
Influenza C  8  3  1  4 15 2 6  3 15 77         
Human metapnuemo virus   1  3  0  0 13 0 5  1  3 13 64        
Parainfluenza virus 1   0  0  0  1  3 0 0  0  0  2  3 39       
Parainfluenza virus 2  0  1  0  0  3 0 1  1  0  2  4  2 14      
Parainfluenza virus 3  3  0  0  0  8 1 2  8  6  6  1  3 5 91     
Parainfluenza virus 4  0  1  0  0  2 0 2  0  3  4  3  1 3  5 24    
Parechovirus  3  1 1 19 12 7 0 3 2 41 0 3 2 9 3 6   
RSV  2  6  9  1 11 1 7  4  5 11  7  5 1  2  2 13 155  
Rhinoviruses  4  7  1  7 31 5 9 10 37 28 16  6 5 20  8 11 10 212 
Positive tests1 
N (%)  
93        
(5.1) 
64    
(3.5) 
44 
(2.4) 
19    
(1.0) 
130 
(7.1) 
17 
(0.9) 
85 
(4.6) 
48 
(2.6) 
64   
(3.5) 
162 
(8.8) 
112 
(6.1) 
56 
(3.1) 
29 
(1.6) 
142 
(7.7) 
42 
(2.3) 
86     
(4.7) 
220 
(12.0) 
358 
(19.5) 
%Co-viral detection2 29.0% 40.6% 27.3% 52.5% 62.3% 70.6% 55.3% 66.7% 79.7% 52.6% 42.9% 30.4% 51.7% 35.9% 42.9% 
 
93.2% 29.5% 40.8% 
1. Represents number of positive tests among all SARI cases tested. Columns do not add up to total positive tests due to detection of multiple virus in some samples; diagonal  of matrix represents mono-infection 
2. Represents proportion of co-viral detection among SARI cases testing positive for the pathogen (listed at column heading) 
 
Table 3. Demographic, seasonal and pathogen factors associated with influenza-positive severe acute respiratory illness 
(SARI) in children, Blantyre Malawi, 2011-2014 
   
 
 
Univariate 
 
Multivariate  
 
All 
Influenza 
Negative 
N (%)1 
Influenza 
Positive 
N (%) 
 
RR2 95% CI 
p-
value 
 
aRR3 95% CI 
p-
value 
Total 2239 1990 249           
              
Gender 
  
 
            Male 1187 (53.0) 1069 (53.7) 118 (47.4) 
 
Ref 
    
Ref 
     Female 1052 (46.9) 921 (46.3) 131 (52.6) 
 
1.4 1.1, 1.9 0.022 
 
1.3 0.9, 1.8 0.069 
   
 
          Age 
  
 
             3 to <6 months  269 (12.0) 250 (12.6) 19 (7.6) 
 
Ref Ref 
   6 to <12 months 576 (25.7) 536 (26.9) 40 (16.1) 
 
0.9 0.5, 1.6 0.615 
 
0.9 0.4, 1.8 0.959 
   12 to <36 months 1071 (47.8) 943 (47.4) 128 (51.4) 
 
1.6 0.9, 2.8 0.084 
 
1.7 1.1, 2.9 0.046 
   36 to <60 months 241 (10.8) 198 (9.9) 43 (17.3) 
 
3.0 1.6, 5.6 <0.001 
 
2.9 1.6, 5.5 <0.001 
   5 to <15 years 82 (3.7) 63 (3.2) 19 (7.6) 
 
2.9 1.3, 6.3 <0.001 2.9 1.3, 6.5 <0.001 
   
 
          Year of recruitment 
  
 
            2011 272 (12.1) 248 (12.5) 24 (9.6) 
 
Ref 
          2012 (vs. 2011) 489 (21.8) 459 (23.1) 30 (12.0) 
 
0.5 0.1, 1.6 0.228 
   2013 (vs. 2011) 811 (36.2) 686 (34.7) 125 (50.2) 
 
2.4 0.8, 7.5 0.139 
 
    
  2014 (vs. 2011) 667 (29.8) 597 (30.0) 70 (28.1) 
 
3.2 1.3, 13.3 0.015 
 
    
   
 
          Season of recruitment 
  
 
          Sep to Dec 726 (32.4) 648 (32.6) 78 (31.3) 
 
Ref 
    
Ref 
   Jan to Apr (rain) 773 (34.5) 654 (32.8) 119 (47.8) 
 
2.7 1.6, 4.4 <0.001 
 
3.3 1.9, 5.4 <0.001 
May to Aug (cool dry) 4 740 (33.1) 688 (34.6) 52 (20.9) 
 
1.6 0.9,  2.8 0.077 
 
2.1 1.2, 3.6 0.009 
   
 
          HIV Positive5 
  
 
          Negative  1973 (94.3) 1747 (94.2) 226 (95.4) 
 
Ref 
        Positive 119 (5.7) 108 (5.8) 11 (4.6) 
 
0.9 0.4 1.7 0.677 
     
   
 
          Weight for age Z score <25  
 
 
          No  1990 (93.2) 1766 (93.2) 224 (92.9) 
 
Ref 
        
Yes 145 (6.8) 128 (6.8) 17 (7.1) 
 
1.2 0.8, 1.6 0.364 
     
   
 
          Malaria 
  
 
          Negative  2160 (96.5) 1913 (96.1) 247 (99.2) 
 
Ref 
    
Ref 
   Positive     79 (3.5) 77 (3.9) 2 (0.8) 
 
0.2 0.1, 0.9 0.030 
 
0.2 0.0 0.8 0.028 
   
 
          Hospitalised  
     No  1750 (78.8) 1549 (77.8) 201 (80.7)  Ref    
     Yes 489 (22.0) 441 (22.2) 48(19.3) 
 
0.8 0.5, 1.1 0.180 
     
   
 
          Blood oxygen 
saturation <90 
  
 
          No 2291 (93.1) 2029 (96.8) 262 (98.1) 
 
Ref 
        Yes 72 (6.9) 67 (3.2) 5 (1.9) 
 
0.7 0.3, 1.8 0.420 
     1. Percentages represent column per cent of column total within each factor 
2. Univariate relative risks from models that included only variable of interest and patient-level kernel smoothing factors to remove auto-correlation in 
residuals 
3. Adjusted relative risks from a multivariable model developed using backwards selection of factors significant at p-value<0.05, and a priori inclusion 
of age and gender. Model included age, gender, season of recruitment, malaria status and patient-level kernel smoothing factors to remove auto-
correlation in residuals 
4. Risk of influenza positive SARI was significantly higher in the rainy season (January to April) compared to the cool dry season (May to August) 
(aRR:; 1.59, 95% CI: 1.04, 2.45) 
5. HIV was measured in 2097 patients,  weight-for-age Z score  was  measured in 2135 patients aged 3 to 59 months 
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Table 4. Incidence of severe acute respiratory illness (SARI) in children residing in Blantyre City, Malawi, 
by SARI type, age and HIV status1 
All Recruited SARI   
     
 HIV Un-infected  HIV infected   
Age group 
Incidence 
per 10,000  95% CI  
Incidence 
per 
10,000  95% CI  IRRHIV 95% CI  
<1 year 89.5 85.8 93.0  155.3 127.3 191.1 
 
1.7 1.41 2.14  
12-59 months 35.8 34.9 36.9  73.3 64.7 87.8 
 
2.0 1.82 2.44  
5-9 years 1.3 1.0 1.6  16.0 9.9 24.2 
 
12.6 7.69 19.21  
10-14 years 0.8 0.7 1.0  7.9 5.5 12.7 
 
9.6 6.52 17.10  
SARI with warning signs 
<1 year 16.5 15.2 18.0  43.1 29.4 60.7  2.6 1.66 3.61  
12-59 months 7.2 6.7 7.5  30.1 24.4 40.3  4.2 3.34 5.91  
5-9 years 0.4 0.3 0.5  9.0 6.0 15.6  24.3 13.51 51.03  
10-14 years 0.1 0.1 0.2  3.3 1.4 6.7  37.7 11.10 93.21  
Hospitalized SARI 
<1 year 12.3 11.1 13.8  25.9 14.9 37.2  2.1 1.1 3.0  
12-59 months 5.4 4.9 5.7  21.9 16.7 30.1  4.1 3.0 5.9  
5-9 years 0.3 0.2 0.4  6.0 2.9 11.0  21.3 9.2 48.7  
10-14 years 0.1 0.0 0.2  3.3 0.7 5.6  37.7 11.1 109.9  
Influenza Positive SARI 
<1 year 6.3 5.3 7.6  6.5 2.2 15.4  1.0 0.40 2.51  
12-59 months 4.9 4.6 5.2  3.7 1.5 8.5  0.7 0.30 1.79  
5-9 years 0.3 0.2 0.4  6.0 2.0 11.8  21.3 6.76 42.07  
10-14 years 0.2 0.2 0.4  0.9 0.2 2.1  8.1 2.79 19.74  
RSV Positive SARI 
<1 year 17.3 16.2 19.3  17.3 8.4 29.2  0.9 0.5 1.7  
12-59 months 3.2 2.9 3.3  4.9 2.0 9.3  1.5 0.6 3.0  
5-9 years 0.1 0.1 0.2  0.0 0.0 0.0  0.0 0.0 0.0  
10-14 years 0.0 0.0 0.0  1.8 0.9 4.6  --2 -- --  
1. Analyses based on 131 HIV infected SARI cases, 53 HIV infected cases of SARI with warning signs, 48 HIV infected hospitalized 
SARI cases, 11 HIV infected influenza positive SARI cases and 13 HIV infected RSV positive SARI cases 
2. Inestimable 
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Table 5. Demographic, seasonal and pathogen factors associated with SARI with warning signs in children, 
Blantyre Malawi, 2011-2013 
     Univariate  Multivariate 
 
Total   
N(%)1 
SARI 
with 
warning 
signs 
N(%) 
SARI 
without 
warning 
signs 
N(%)  RR2 95% CI 
p-
value  aRR3 95% CI 
p-
value 
 1505 1115  390            
              
Gender              
  Male 820 (54.5) 603 (54.1) 217 (55.6)           
  Female 685 (45.5) 512 (45.9) 173 (44.4) 
 
0.83 0.65 1.07 0.157 
 
0.80 0.62 1.04 0.091 
            
Age 
 
  
             3 to <6 months  171 (11.3) 137 (12.3) 34 (8.7) 
 
Ref 
    
Ref
      6 to <12 months 390 (25.9) 294 (26.4) 96 (24.6) 
 
1.1 0.7 1.9 0.575 
 
1.1 0.7 1.8 0.723 
   12 to <36 months 720 (47.8) 525 (47.1) 195 (50.0) 
 
1.2 0.8 2.0 0.261 
 
1.4 0.9 2.2 0.188 
   36 to <60 months 164 (10.9) 122 (10.9) 42 (10.8) 
 
1.2 0.7 2.1 0.553 
 
1.2 0.6 2.2 0.524 
   5 to <15 years 60 (3.9) 37 (3.3) 23 (5.9) 
 
1.5 0.7 3.2 0.300 
 
1.5 0.6 3.1 0.322 
   
 
          Year of recruitment 
  
 
            2011 248 (16.5) 105 (9.4) 143 (36.7) 
            2012 (vs. 2011) 464 (30.8) 361 (32.4) 103 (26.4) 
 
0.9 0.4 2.2 0.801 
 
   
  2013 (vs. 2011) 793 (52.7) 649 (58.2) 144 (36.9) 
 
0.9 0.4 2.3 0.820 
 
    
  
  
      
    
Season of recruitment 
 
  
      
    
Sep to Dec 572 (38.0) 445 (39.9) 127 (32.6) 
 
Ref 
    
    
Jan to April (rain) 482 (32.0) 386 (34.6) 96 (24.6) 
 
2.9 1.7 4.8 <.0001 
 
2.4 1.6 3.8 <0.001 
May to August (cool dry) 451 (29.9) 284 (25.5) 167 (42.8) 
 
0.9 0.6 1.2 0.461 
 
0.8 0.59 1.2 0.319 
  
  
      
    
HIV Positive 94 (6.2) 53 (4.8) 41 (10.5) 
 
1.9 1.2 3.0 0.008 
 
2.4 1.4 3.9 <0.001 
   
 
          Mid-Upper Arm 
Circumference <11.5 17 (1.1) 13 (1.2) 5 (1.3) 
 
1.2 0.5 2.8 0.706 
 
  
  
  
  
       
 
  
Appendix –CONSORT diagram 
Weight for age Z score<3  73 (4.9) 52 (4.7) 21 (5.4) 
 
1.3 0.8 2.2 0.314 
  
 
  
  
  
       
 
  Influenza 
 
  
            Negative 1332 (88.5) 986 (88.4) 346 (88.7) 
 
Ref 
          A- not subtyped/mixed 6 (0.0) 4 (0.0) 2 (0.0) 
 
2.1 0.4 12.0 0.413 
       A(H3N2) 74 (4.9) 62 (5.6) 12 (3.1) 
 
0.6 0.3 1.3 0.207 
       A(H1N1)pdm09 41 (2.7) 24 (2.2) 17 (4.4) 
 
1.9 0.9 4.2 0.642 
       B 52 (3.5) 41 (3.7) 11 (2.8) 
 
0.9 0.5 2.1 0.978 
              
Co-viral detection4 309 214 (19.2) 95 (24.4) 
 
1.1 0.8 1.3 0.375 
      
PCR Positive               
Influenza C  17 (1.1) 14 (1.3) 3 (0.7) 
 
0.6 0.2 2.2 0.469 
     
  
  
          Parainfluenza 1  52 (3.5) 41 (3.7) 11 (2.8) 
 
0.8 0.4 1.5 0.427 
     
  
  
          Parainfluenza 2  29 (1.9) 20 (1.8) 9 (2.3) 
 
1.3 0.6 2.9 0.526 
      
 
  
          Parainfluenza 3 127 (8.4) 95 (8.5) 32 (8.2) 
 
0.9 0.6 1.5 0.849 
     
  
  
          Parainfluenza 4 38 (2.5) 29 (2.6) 9 (2.3) 
 
0.9 0.4 1.9 0.751 
     
   
 
          RSV (A&B) 164 (10.9) 94 (8.4) 70 (17.9) 
 
2.6 1.9 3.6 <.0001 
 
1.9 1.3 3.0 0.002 
  
  
      
    
Adenovirus 136 (9.0) 97 (8.7) 39 (10.0) 
 
1.2 0.8 1.7 0.659 
     
  
  
          Enterovirus 50 (3.3) 38 (3.4) 12 (3.1) 
 
0.9 0.5 1.7 0.754 
     
  
  
          Rhinovirus 301 (20.0) 224 (20.1) 77 (19.7) 
 
0.9 0.7 1.4 0.895 
     
  
  
          Bocavirus 102 (6.8) 71 (6.4) 31 (7.9) 
 
1.2 0.8 1.9 0.286 
     
  
  
          Coronavirus 43 66 (4.4) 43 (3.9) 23 (5.9) 
 
1.5 0.9 2.6 0.092 
 
  
  
          Coronavirus 63 48 (3.2) 40 (3.6) 8 (2.1) 
 
0.6 0.3 1.2 0.142 
 
0.2 0.07 0.70 0.010 
   
 
          Coronavirus 229 16 (1.1) 11 (0.9) 5 (1.3) 
 
1.3 0.5 3.7 0.625 
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          Human metapneumovirus 25 (1.7) 19 (1.7) 6 (1.5) 
 
0.9 0.5 1.4 0.529 
     
  
  
          Parechovirus 74 (4.9) 56 (5.0) 18 (4.6) 
 
0.9 0.5 1.6 0.634 
     
  
  
          Malaria  Positive 42 (2.8) 24 (2.2) 18 (4.6) 
 
2.2 1.1 4.6 0.025 
 
2.2 1.1 4.6 0.029 
1. Percentages represent  factor column totals, or per  cent of  all SARI cases assessed for the factor  
2. Univariate relative risks from models that included only variable of interest and patient-level kernel smoothing factors to remove auto-
correlation in residuals 
3. Adjusted relative risks from a multivariable model developed using backwards selection of factors significant at p-value<0.05, and a priori 
inclusion of age, and gender. Model included age, gender, season of recruitment, HIV, RSV, Coronavirus 43, malaria status and patient-level 
kernel smoothing factors to remove auto-correlation in residuals 
4. 362/1835  (19.7%) of all SARI cases with multiplex PCR data had viral co-detection 
 
  
 
 
 
 



